UniQure gene therapy delivers lasting efficacy in hemB, but Spark FIX comparisons continue to cast a shadow over data – FierceBiotech
FierceBiotech |
UniQure gene therapy delivers lasting efficacy in hemB, but Spark FIX comparisons continue to cast a shadow over data
FierceBiotech UniQure has posted fresh data from a phase 1/2 trial of its hemophilia B gene therapy. The 12-month low-dose data and six-month high-dose results link AMT-060 to the near-cessation of spontaneous bleeding and a sharp drop in Factor IX (FIX) replacement … UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data |
